ASH 2011: Pediatric Acute Leukemia Therapies Informed by Molecular Analysis of High-Risk Disease
Dr. Stuart Sheldon Winter is a professor at the department of pediatrics – division of hematology and oncology. He has 20 years of experience in the field and he is the chief of the UNM Cancer Center, New Mexico.
In this interview on Pediatric Acute Leukemia Therapies Informed by Molecular Analysis of High-Risk Disease Dr Winter discusses Pediatric Acute Leukemia Therapies Informed by Molecular Analysis of High-Risk Disease
Questions
Could you please share with our viewers the scope of your research interest?
In one of the “Education Programs” of ASH 2011 on “Pediatric Malignancies: Clinical Implications of Advances in Leukemia Biology”, you presented on “Pediatric Acute Leukemias Informed by Molecular Analysis of High-Risk Disease”. Could you tell our viewers something about your presentation?
In your presentation, you discussed several recently described genetic aberrations found in high-risk acute myeloid and lymphocytic leukemias, what brought about the interest in this and how would this influence the diagnosis of high-risk disease for pediatric acute leukemias?
In pediatric acute leukemias, it has been shown that signaling pathways are disrupted by molecular aberrations causing the disease. How can this affect the approach to management of pediatric leukemias?
Do we have a current clinical therapeutic recommendation based on these?
What are the challenges would pediatric acute leukemia therapies augmented by molecular analysis of high-risk disease face?
How will future treatments for pediatric acute leukemias be affected by some of the scientific advances presented at the 2011 American Society of Hematology meeting?
